login
  Password reminder

Subscribe Edit your account | View your account

Interventional News
Contact the editor Visit Interventional News Twitter feed Visit Interventional News Facebook page
 




Featured Highlights
21 - 40 of 135   Items
NICE recommends selective internal radiation therapy for treatment of primary and secondary liver cancer

NICE recommends selective internal radiation therapy for treatment of primary and secondary liver cancer

Wednesday, 31 Jul 2013
BTG announced on 30 July that the National Institute for Health and Clinical Excellence (NICE) has issued guidance recommending the use of selective internal radiation therapy (SIRT), which includes TheraSphere, for patients with liver cancer across the NHS. NICE recommends selective internal radiation therapy for treatment of primary and secondary liver cancer
Surefire infusion system safe and effective for delivery of Y90

Surefire infusion system safe and effective for delivery of Y90

Wednesday, 10 Jul 2013
Case reports published in the Journal of Cardiovascular and Interventional Radiology show that the Surefire Infusion System can safely and effectively Y90 in order to treat inoperable liver cancer. Surefire infusion system safe and effective for delivery of Y90
Sirtex to distribute Surefire Medical’s infusion system in Australia and Asia-Pacific markets

Sirtex to distribute Surefire Medical’s infusion system in Australia and Asia-Pacific markets

Wednesday, 26 Jun 2013
Sirtex Medical and US-based Surefire Medical has announced a sales and marketing partnership to distribute Surefire’s range of innovative infusion systems and specialty catheters for the interventional radiology and oncology markets. Sirtex to distribute Surefire Medical’s infusion system in Australia and Asia-Pacific markets
SARAH study enroling patients throughout France for the treatment of primary liver cancer

SARAH study enroling patients throughout France for the treatment of primary liver cancer

Tuesday, 25 Jun 2013
Launched by the Assistance Publique Hôpitaux de Paris, France, in December 2011, SARAH (Sorafenib versus radioembolization in advanced hepatocellular carcinoma), a French national collaborative randomised controlled trial of radioembolization with yttrium-90 resin microspheres vs. sorafenib in advanced hepatocellular carcinoma has announced it is seeking to enrol 400 patients. SARAH study enroling patients throughout France for the treatment of primary liver cancer
Radiosurgery treatments for lung cancer using Varian Medical Systems Technologies presented at ESTRO

Radiosurgery treatments for lung cancer using Varian Medical Systems Technologies presented at ESTRO

Tuesday, 07 May 2013
Cancer experts have reported future trends and progress in radiotherapy treatments for lung cancer using motion management and tumour-tracking technologies from Varian Medical Systems at the annual ESTRO Forum (19–23 April 2013, Geneva, Switzerland). Radiosurgery treatments for lung cancer using Varian Medical Systems Technologies presented at ESTRO
Cost effective prostate cancer treatment underused in the UK

Cost effective prostate cancer treatment underused in the UK

Friday, 03 May 2013
Better outcomes can be achieved for prostate cancer patients using brachytherapy, a highly targeted form of radiotherapy, compared to surgery according to study findings conducted by Panaxea, The University of Twente, The Netherlands. Cost effective prostate cancer treatment underused in the UK
Elekta receives FDA 510(k) clearance for Versa HD Radiation Therapy System for cancer treatment

Elekta receives FDA 510(k) clearance for Versa HD Radiation Therapy System for cancer treatment

Friday, 12 Apr 2013
Elekta recently received 510(k) clearance from the US Food and Drug Administration (FDA) which allows the company to begin shipping and installation of all components of the Versa HD system within the USA. Elekta receives FDA 510(k) clearance for Versa HD Radiation Therapy System for cancer treatment

Medwaves announces the first successful use of hot and cold thyroid nodules with AveCure Microwave Ablation System and radioiodine

Friday, 12 Apr 2013
Hudayi Korkusuz, Hospital of Johann Wolfgang Goethe University, Frankfurt, Germany, has conducted the first combination treatment of microwave ablation and radiotherapy, according to a press release. Medwaves announces the first successful use of hot and cold thyroid nodules with AveCure Microwave Ablation System and radioiodine

Nordion to host European-based educational and scientific meetings for liver cancer specialists

Thursday, 11 Apr 2013
On 11–12 April, Nordion will host its 3rd European TheraSphere User Group Meeting in Vienna, Austria, and on 18 April, Nordion will offer a Satellite Symposium at the 3rd Interdisciplinary Treatment of Liver Tumors (ITLT) Meeting in Essen, Germany, according to a company release. Nordion to host European-based educational and scientific meetings for liver cancer specialists

BSD Medical announces distribution agreement with Terumo Europe for the MicroThermX Microwave Ablation System

Thursday, 11 Apr 2013
BSD Medical announced today that the company has signed an exclusive, long-term, multi-million dollar distribution agreement with Terumo Europe, a wholly owned subsidiary of Terumo Corporation, for the MicroThermX Microwave Ablation System. BSD Medical announces distribution agreement with Terumo Europe for the MicroThermX Microwave Ablation System
Nordion to host interactive TheraSphere educational session at the Society of Interventional Radiology Annual Scientific Meeting

Nordion to host interactive TheraSphere educational session at the Society of Interventional Radiology Annual Scientific Meeting

Thursday, 11 Apr 2013
Nordion a leading provider of products and services for the prevention, diagnosis and treatment of disease, will host an educational session called “TheraSphere test flight interactive: How to treat or should I treat?” at the Society for Interventional Radiology’s (SIR) Annual Scientific Meeting (13–18 April, New Orleans, USA). Nordion to host interactive TheraSphere educational session at the Society of Interventional Radiology Annual Scientific Meeting
First centre in Hong Kong treats patients with CyberKnife and TomoTherapy systems

First centre in Hong Kong treats patients with CyberKnife and TomoTherapy systems

Friday, 22 Mar 2013
Accuray has reported that the Hong Kong Adventist Oncology Center has treated patients with the CyberKnife and TomoTherapy systems. First centre in Hong Kong treats patients with CyberKnife and TomoTherapy systems
ONCOassist oncology app has received the CE mark

ONCOassist oncology app has received the CE mark

Thursday, 21 Mar 2013
Portable Medical, according to the company website, has received the CE mark for its oncology decision-making smartphone app—ONCOassist. The app was developed in conjunction with doctors and is classed as a medical device in accordance with EU regulations. ONCOassist oncology app has received the CE mark

Boston Scientific announces its support activities for Awareness of Colorectal Cancer Month

Thursday, 14 Mar 2013
Boston Scientific announced it is supporting Colorectal Cancer Awareness Month with a range of awareness-raising activities throughout March. Boston Scientific announces its support activities for Awareness of Colorectal Cancer Month
Nordion launches updated TheraSphere website for liver cancer physicians, patients and carers

Nordion launches updated TheraSphere website for liver cancer physicians, patients and carers

Thursday, 07 Mar 2013
TheraSphere.com, the new TheraSphere website, provides resources and targeted information about radioembolization therapy and is available as an iPad app, according to a company release. Nordion launches updated TheraSphere website for liver cancer physicians, patients and carers

Study data suggests 95% cure rate for men with prostate cancer using high intensity focused ultrasound

Thursday, 07 Mar 2013
Prostate patients, according to data announced by the Diagnostic Center for Disease, Florida, USA, said that there could be a 95% cure rate when biopsy is used in conjunction with 3 telsa magnetic resonance imaging spectroscopy. Study data suggests 95% cure rate for men with prostate cancer using high intensity focused ultrasound

Surefire Medical infusion system can prevent embolics entering non-target vessels for the treatment of liver cancer

Thursday, 07 Mar 2013
According to Surefire Medical and a study published in CardioVascular and Interventional Radiology, the Surefire infusion system can prevent embolics, such as those used for treating liver cancer, entering distal non-target vessels. Surefire Medical infusion system can prevent embolics entering non-target vessels for the treatment of liver cancer
TACE procedure in Japan and Korea was favourable for overall survival in hepatocellular carcinoma patients

TACE procedure in Japan and Korea was favourable for overall survival in hepatocellular carcinoma patients

Monday, 04 Mar 2013
According to results of a study published in the Journal of Vascular and Interventional Radiology, a transcatheter arterial chemoembolization (TACE) procedure using an emulsion of lipidol, an anthracycline agent and gelatin sponge particles, in Asia, was favourable for patient outcomes compared with Western TACE. TACE procedure in Japan and Korea was favourable for overall survival in hepatocellular carcinoma patients
Coding Strategies offers new radiology and oncology HCPCS resource guides

Coding Strategies offers new radiology and oncology HCPCS resource guides

Monday, 04 Mar 2013
According to a company release, designed for quick and easy reference, Coding Strategies has launched two new HCPCS resource guides for radiology and oncology. Coding Strategies offers new radiology and oncology HCPCS resource guides
Lower rates of post-embolization syndrome and fatigue with smaller drug-eluting beads for hepatocellular carcinoma

Lower rates of post-embolization syndrome and fatigue with smaller drug-eluting beads for hepatocellular carcinoma

Friday, 22 Feb 2013
In a study published in the Journal of Vascular and Interventional Radiology, Siddharth A Padia and colleagues compared 100–300µm and 300–500µm drug-eluting beads for the treatment of hepatocellular carcinoma patients. Lower rates of post-embolization syndrome and fatigue with smaller drug-eluting beads for hepatocellular carcinoma
Found: 135   Displaying: 21-40
Results: 1 2 3 4 5 Next Go to:
Related Section
Clinical Trials
Interventional Oncology News
Interventional Oncology Supplement
Key Opinion Leaders discuss the role of Biocompatible's DC Bead at CIRSE and ILCA
IR Views
Literature
Oncology Useful Links

Related Feeds

Latest News




Monday, 31 Mar 2014

Features





Profiles





Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions